KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

Nektar Therapeutics (NKTR) Receivables - Other (2018 - 2025)

Nektar Therapeutics has reported Receivables - Other over the past 8 years, most recently at $600000.0 for Q4 2025.

  • Quarterly results put Receivables - Other at $600000.0 for Q4 2025, down 45.45% from a year ago — trailing twelve months through Dec 2025 was $600000.0 (down 45.45% YoY), and the annual figure for FY2025 was $600000.0, down 45.45%.
  • Receivables - Other for Q4 2025 was $600000.0 at Nektar Therapeutics, down from $1.1 million in the prior quarter.
  • Over the last five years, Receivables - Other for NKTR hit a ceiling of $1.4 million in Q4 2021 and a floor of $500000.0 in Q4 2023.
  • Median Receivables - Other over the past 5 years was $700000.0 (2022), compared with a mean of $860000.0.
  • Biggest five-year swings in Receivables - Other: tumbled 72.55% in 2021 and later surged 120.0% in 2024.
  • Nektar Therapeutics' Receivables - Other stood at $1.4 million in 2021, then crashed by 50.0% to $700000.0 in 2022, then fell by 28.57% to $500000.0 in 2023, then soared by 120.0% to $1.1 million in 2024, then tumbled by 45.45% to $600000.0 in 2025.
  • The last three reported values for Receivables - Other were $600000.0 (Q4 2025), $1.1 million (Q4 2024), and $500000.0 (Q4 2023) per Business Quant data.